{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/alopecia-androgenetic-female/","result":{"data":{"firstChapter":{"id":"ed7eb17b-bb56-55c8-93ed-c69fffb8ffb2","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field cb4daf10-2357-4599-bbdf-7065da3a2316 --><h1>Alopecia, androgenetic - female: Summary</h1><!-- end field cb4daf10-2357-4599-bbdf-7065da3a2316 -->","htmlStringContent":"<!-- begin item 04b6f872-bf81-4cf5-a5c3-8d96806dfdec --><!-- begin field 4d4fbc44-8cfb-460d-b241-374be0c78d7d --><ul><li>Androgenetic alopecia (or female pattern hair loss) describes a distinctive pattern of hair loss, which may occur in genetically predisposed women and is thought to be androgen dependent. Hair loss is usually diffuse and affects the top of the scalp.</li><li>The underlying pathological process involves pigmented terminal hairs gradually being replaced by smaller, less pigmented hairs similar to vellus hairs.</li><li>The prevalence and severity of androgenetic alopecia in women increases greatly after the menopause and affects about a third of white women aged 70 years and older.</li><li>Complications of androgenetic alopecia may include adverse psychosocial effects.</li><li>Hair loss in women tends to progress over time, but the rate of progression is unpredictable. Women with androgenetic alopecia rarely go completely bald.</li><li>The diagnosis is usually made from the history and clinical findings alone:<ul><li>A history should be taken to assess the severity, impact, and possible causes of hair loss. This should include a gynaecological/obstetric history and specific questions about features of androgen excess.</li></ul></li><li>The pattern and distribution of hair thinning should be assessed, and the scalp inspected. </li><ul><li>The typical pattern of hair loss involves slowly progressive and often diffuse reduction in the density of hair at the crown, with retention of the frontal hairline.</li></ul><li>An underlying cause or alternative diagnosis for the hair loss should be suspected if assessment reveals:<ul><li>Systemic disease, such as a recent severe infection, iron deficiency, or hypothyroidism.</li><li>Exposure to certain drugs, such as antidepressants, anabolic steroids, progestogens, carbimazole, or chemotherapy.</li><li>Extreme dietary habits or rapid weight loss.</li><li>Inflammation, papules or pustules, scaling, or scarring of the scalp.</li></ul></li><li>Laboratory testing for the diagnosis of androgenetic alopecia is generally unnecessary.<ul><li>Tests for thyroid function, full blood count, and ferritin level should be considered, particularly if telogen effluvium is suspected, the presentation is atypical, or there are features that suggest anaemia or hypothyroidism.</li><li>Basic endocrine investigations should be considered if there are features of androgen excess.</li></ul></li><li>The natural course of the condition, what the woman may expect in terms of continued hair thinning, and the woman's wishes regarding treatment and/or aesthetic options should be discussed.<br></li><li>Topical minoxidil 2% solution is licensed for use in female androgenetic alopecia:<ul><li>It is not prescribable on the NHS but can be bought over-the-counter or prescribed privately.</li><li>Hair regrowth may not be noticed for 3-6 months.</li><li>Stopping treatment will lead to loss of all results within 6-12 months, and the rebound shedding may be severe.</li></ul></li><li>Aesthetic options such as hairpieces and wigs, hairstyling, and surgical hair transplantation can be considered, although these are not usually available on the NHS.</li><li>Referral to the appropriate specialist should be considered if the woman has:<ul><li>An atypical presentation or extensive hair loss.</li><li>Clinical or biochemical evidence of androgen excess.</li><li>Adverse psychosocial effects.<br></li><li>No response to available treatments in primary care.<br></li></ul></li></ul><!-- end field 4d4fbc44-8cfb-460d-b241-374be0c78d7d --><!-- end item 04b6f872-bf81-4cf5-a5c3-8d96806dfdec -->","topic":{"id":"34cafa57-9383-5d80-b924-585fddfaf630","topicId":"ee168cae-489c-42c8-b09e-953c3911c90a","topicName":"Alopecia, androgenetic - female","slug":"alopecia-androgenetic-female","aliases":[],"chapters":[{"id":"ed7eb17b-bb56-55c8-93ed-c69fffb8ffb2","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"50eed0df-a1f0-5171-9181-43ae31f74c24","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"a335b9ba-ae97-56fc-8f3c-67269d2cebee","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"423c1f05-2850-5fc3-9dfe-32260c543c30","slug":"changes","fullItemName":"Changes"},{"id":"98782d6b-86e0-52c6-874d-d38c3a7b8b43","slug":"update","fullItemName":"Update"}]},{"id":"c3b76113-c0a5-51d2-9626-e50262eb0b51","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"26174a6e-62fc-5925-bdc7-6dec1e3cc672","slug":"goals","fullItemName":"Goals"},{"id":"268ede25-aeb2-59d0-8650-e83fb2b7237c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d0de2e8e-6151-5970-b442-dab292556f28","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"beac34dd-51e9-51be-b40d-b68c2f22bab0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7238b814-3ad5-52e6-ad73-5c5e25e26035","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16239c30-d709-5fbe-b215-e9181602c63f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3e8ded1e-bf8c-5ab8-bae3-0a3718045265","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"2a41bf35-6b01-5146-9673-3480759cf2b2","slug":"definition","fullItemName":"Definition"},{"id":"3f9115db-2801-58d5-8b38-614632cc8518","slug":"causes","fullItemName":"Causes"},{"id":"22dc1f21-64e2-59d3-9248-27696a2ff2f3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d994014c-2572-5645-8d46-23c950e5e12f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b2055ae4-a6c4-5ea6-8abb-2ada0bfe997f","slug":"complications","fullItemName":"Complications"},{"id":"f6b263b5-2a9d-5889-b83a-31313b2349ba","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c98a08a0-1460-5525-b53e-e7dd062f5271","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"d05f7dc4-15b4-51a7-9040-1f13534d2bcd","slug":"diagnosis-assessment","fullItemName":"Diagnosis and assessment"},{"id":"5c4491cc-a38e-5798-9ea5-303e2514c88a","slug":"investigations","fullItemName":"Investigations"},{"id":"8ec69667-1bf4-5d04-8c65-48f0cca236b3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"dcc3e89f-77d3-55b8-96a0-7f18236d81ed","slug":"management","fullItemName":"Management","subChapters":[{"id":"84a05021-8d2e-500f-bac8-1152758fd81c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"d947b9be-2aca-5db0-bde3-bd1288f9fe15","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"52c6980c-f25c-5733-a13e-000bf03bd936","slug":"topical-minoxidil-2percent-solution","fullItemName":"Topical minoxidil 2% solution"}]},{"id":"1f4c5c98-e1a3-5353-af89-7c80d4173e69","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"a13caaee-1053-53e3-9663-af5cdb6967c3","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"c996db3c-f9be-5ca7-8fbf-6d8cc2a1dccf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"66cae4ab-b2ad-5800-b305-3061debc9954","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4f39a0f4-1a5f-51fa-ad3f-0bc3472e20ae","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ebbfb681-3de5-545e-9479-c10e9c16eac3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fb1f7555-0114-5914-8728-1ba58437da39","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2ef85d5b-cf19-51e6-b768-e1dfbdc625a0","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"34cafa57-9383-5d80-b924-585fddfaf630","topicId":"ee168cae-489c-42c8-b09e-953c3911c90a","topicName":"Alopecia, androgenetic - female","slug":"alopecia-androgenetic-female","aliases":[],"topicSummary":"Androgenetic alopecia (or female pattern hair loss) describes a distinctive pattern of hair loss, which may occur in genetically predisposed women","lastRevised":"Last revised in May 2016","nextPlannedReviewBy":"2021-05-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2021-04","nextPlannedReviewByDisplay":"April 2021","specialities":[{"id":"50071c38-ab10-5ab8-ac70-6bd19a96c24e","name":"Skin and nail","slug":"skin-nail"},{"id":"0c813417-9691-5826-9371-c4bec6c53f06","name":"Women's health","slug":"womens-health"}],"chapters":[{"id":"ed7eb17b-bb56-55c8-93ed-c69fffb8ffb2","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"50eed0df-a1f0-5171-9181-43ae31f74c24","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"a335b9ba-ae97-56fc-8f3c-67269d2cebee","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"423c1f05-2850-5fc3-9dfe-32260c543c30","slug":"changes","fullItemName":"Changes"},{"id":"98782d6b-86e0-52c6-874d-d38c3a7b8b43","slug":"update","fullItemName":"Update"}]},{"id":"c3b76113-c0a5-51d2-9626-e50262eb0b51","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"26174a6e-62fc-5925-bdc7-6dec1e3cc672","slug":"goals","fullItemName":"Goals"},{"id":"268ede25-aeb2-59d0-8650-e83fb2b7237c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d0de2e8e-6151-5970-b442-dab292556f28","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"beac34dd-51e9-51be-b40d-b68c2f22bab0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7238b814-3ad5-52e6-ad73-5c5e25e26035","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16239c30-d709-5fbe-b215-e9181602c63f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3e8ded1e-bf8c-5ab8-bae3-0a3718045265","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"2a41bf35-6b01-5146-9673-3480759cf2b2","slug":"definition","fullItemName":"Definition"},{"id":"3f9115db-2801-58d5-8b38-614632cc8518","slug":"causes","fullItemName":"Causes"},{"id":"22dc1f21-64e2-59d3-9248-27696a2ff2f3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d994014c-2572-5645-8d46-23c950e5e12f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b2055ae4-a6c4-5ea6-8abb-2ada0bfe997f","slug":"complications","fullItemName":"Complications"},{"id":"f6b263b5-2a9d-5889-b83a-31313b2349ba","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c98a08a0-1460-5525-b53e-e7dd062f5271","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"d05f7dc4-15b4-51a7-9040-1f13534d2bcd","slug":"diagnosis-assessment","fullItemName":"Diagnosis and assessment"},{"id":"5c4491cc-a38e-5798-9ea5-303e2514c88a","slug":"investigations","fullItemName":"Investigations"},{"id":"8ec69667-1bf4-5d04-8c65-48f0cca236b3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"dcc3e89f-77d3-55b8-96a0-7f18236d81ed","slug":"management","fullItemName":"Management","subChapters":[{"id":"84a05021-8d2e-500f-bac8-1152758fd81c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"d947b9be-2aca-5db0-bde3-bd1288f9fe15","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"52c6980c-f25c-5733-a13e-000bf03bd936","slug":"topical-minoxidil-2percent-solution","fullItemName":"Topical minoxidil 2% solution"}]},{"id":"1f4c5c98-e1a3-5353-af89-7c80d4173e69","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"a13caaee-1053-53e3-9663-af5cdb6967c3","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"c996db3c-f9be-5ca7-8fbf-6d8cc2a1dccf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"66cae4ab-b2ad-5800-b305-3061debc9954","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4f39a0f4-1a5f-51fa-ad3f-0bc3472e20ae","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ebbfb681-3de5-545e-9479-c10e9c16eac3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fb1f7555-0114-5914-8728-1ba58437da39","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2ef85d5b-cf19-51e6-b768-e1dfbdc625a0","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"34cafa57-9383-5d80-b924-585fddfaf630"}},"staticQueryHashes":["3666801979"]}